Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News KaloBios Pharmaceuticals, Inc. KBIO

Healthcare Biotechnology
"KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company focuses on developing medicines for patients with neglected and rare diseases through innovative and responsible business models."

Recent & Breaking News (OTCPK:KBIO)

KaloBios To Change Company Name To Humanigen, Inc.

GlobeNewswire July 27, 2017

KaloBios Receives $5.0M in New Funding Commitment From Existing Investors

GlobeNewswire July 12, 2017

KaloBios Receives Orphan Drug Designation for Benznidazole in the Treatment of Chagas Disease

GlobeNewswire July 11, 2017

Benznidazole IND for Chagas Disease Receives Clearance by FDA

GlobeNewswire June 27, 2017

KaloBios Upgrades Stock to OTCQB Market

GlobeNewswire June 26, 2017

KaloBios CEO to Present at Two Upcoming Investor Conferences

GlobeNewswire May 31, 2017

KaloBios Submits IND Application for Benznidazole to FDA

GlobeNewswire May 30, 2017

KaloBios Comments on Recent Scientific Publication Reporting Significantly Higher Risk of Death Associated With Chagas Infection

GlobeNewswire May 25, 2017

KaloBios to Host Company Overview Webinar on May 10

GlobeNewswire May 3, 2017

Benznidazole on Track in Progress to IND and NDA Submissions

GlobeNewswire April 6, 2017

KaloBios to Participate in Inaugural U.S. Chagas Conference

GlobeNewswire March 30, 2017

KaloBios Receives M&A Advisor 2017 Turnaround Award

GlobeNewswire March 27, 2017

KaloBios Receives $5.5M in New Financing From Existing Investors

GlobeNewswire March 23, 2017

KaloBios to Present at 29th Annual ROTH Conference

GlobeNewswire March 9, 2017

KaloBios to Present at Disruptive Growth & Healthcare Conference

GlobeNewswire February 13, 2017

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of KaloBios Pharmaceuticals, Inc. -- KBIO

GlobeNewswire February 9, 2017

KaloBios Announces Positive Guidance from FDA for Benznidazole

GlobeNewswire January 5, 2017

KaloBios CEO to Participate at FDA/CMS Summit

GlobeNewswire December 13, 2016

KaloBios Highlights Priority Milestones in Letter to Stakeholders

GlobeNewswire December 5, 2016

KaloBios to Present at JMML International Symposium

GlobeNewswire November 29, 2016